Xponance Inc. Purchases 113 Shares of Glaukos Co. (NYSE:GKOS)

Xponance Inc. increased its position in shares of Glaukos Co. (NYSE:GKOS) by 4.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 2,879 shares of the medical instruments supplier’s stock after buying an additional 113 shares during the quarter. Xponance Inc.’s holdings in Glaukos were worth $229,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. Arizona State Retirement System grew its holdings in shares of Glaukos by 2.1% during the third quarter. Arizona State Retirement System now owns 13,040 shares of the medical instruments supplier’s stock worth $981,000 after buying an additional 264 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Glaukos by 17.3% during the third quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock valued at $137,000 after purchasing an additional 270 shares during the last quarter. Mariner LLC boosted its position in Glaukos by 7.1% during the third quarter. Mariner LLC now owns 6,218 shares of the medical instruments supplier’s stock valued at $468,000 after purchasing an additional 411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in Glaukos by 2.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,542 shares of the medical instruments supplier’s stock valued at $1,951,000 after purchasing an additional 610 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Glaukos by 7.9% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,700 shares of the medical instruments supplier’s stock valued at $851,000 after purchasing an additional 784 shares during the last quarter. 99.04% of the stock is currently owned by institutional investors.

Insider Transactions at Glaukos

In other news, CFO Alex R. Thurman sold 1,372 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $100.54, for a total transaction of $137,940.88. Following the completion of the transaction, the chief financial officer now owns 52,532 shares of the company’s stock, valued at approximately $5,281,567.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In other Glaukos news, COO Joseph E. Gilliam sold 59,801 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.47, for a total value of $6,008,206.47. Following the completion of the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at approximately $10,232,367.15. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Alex R. Thurman sold 1,372 shares of the company’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $100.54, for a total value of $137,940.88. Following the completion of the transaction, the chief financial officer now directly owns 52,532 shares of the company’s stock, valued at approximately $5,281,567.28. The disclosure for this sale can be found here. In the last quarter, insiders sold 242,357 shares of company stock valued at $22,857,372. Corporate insiders own 6.40% of the company’s stock.

Glaukos Stock Performance

NYSE:GKOS opened at $99.48 on Friday. The stock has a fifty day moving average price of $92.42 and a 200-day moving average price of $81.74. The company has a market cap of $4.99 billion, a price-to-earnings ratio of -35.78 and a beta of 1.08. The company has a debt-to-equity ratio of 0.77, a quick ratio of 4.78 and a current ratio of 5.34. Glaukos Co. has a fifty-two week low of $45.38 and a fifty-two week high of $103.66.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, February 21st. The medical instruments supplier reported ($0.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.07). Glaukos had a negative net margin of 42.79% and a negative return on equity of 22.67%. The company had revenue of $82.40 million for the quarter, compared to the consensus estimate of $81.00 million. During the same quarter in the previous year, the company posted ($0.53) earnings per share. The business’s revenue was up 15.7% compared to the same quarter last year. As a group, equities analysts anticipate that Glaukos Co. will post -2.18 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research report on Tuesday, February 27th. Citigroup increased their price target on Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research report on Monday, March 25th. Mizuho increased their price target on Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research report on Thursday, April 11th. Truist Financial reaffirmed a “buy” rating and issued a $110.00 price objective on shares of Glaukos in a research report on Monday, April 8th. Finally, Stifel Nicolaus reissued a “buy” rating and set a $110.00 price target on shares of Glaukos in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $99.80.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.